Industry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels

Size: px
Start display at page:

Download "Industry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels"

Transcription

1 Industry Experience in Clinical Trials Management Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels

2 Stakeholders in clinical research Critical activities to ensure patient safety or well being Proper protocol feasibility Rigorous site selection Close monitoring Amendments to protocols How they do it in EU What does ICH say? Safety reporting in ICH Countries Asia countries example The Role of Ethics committees Outline

3 Stakeholders in clinical research Sponsor Regulatory Authority Monitor/ CRA* Patient IRB Share responsibility * Monitor/ CRA: Clinical Research Associate from Sponsor Investigator

4 Proper Feasibility Process Program feasibility product Protocol input from countries Proper clinical development plan Protocol feasibility study Confirm country allocation Site feasibility site Confirm pt/site no per country PCO conduct pre-trial assessment Confirm individual site participation

5 Rigorous site selection Essential Features Available pt pool/facility Well-established clinical operations infrastructure/site management organization Institution Qualified, dedicated or committed investigators Properly Trained site staffs/low turnover/available time Build in clinical trial process into Hospital procedure to ensure the requirement can be met per protocol Transparent budget management process

6 Close Monitoring Education and Qualification of Monitors CRA Certification Program Protocol specific training/ta training Annual re-certification of monitors/ sharing audit trend Monitoring Process Measuring adherence to investigational plan and protocols Support consistent and prompt monitoring of visit data Monitor Oversight and Controls Implement protocol specific comonitoring visits Improved Escalation plan / documented review MVR Investigator Site Selection Formal Documentation of site ability to meet study requirements Mandate web GCP/Study Training for Investigators 6

7 Amendments to Protocols Why there is a need for protocol amendment(s)? things evolve and change during development phase, Inclusion/exclusion criteria, study visit, tests, change based on trial execution New information related to IP, comparator, disease, procedures or treatment that affect the trial conduction Changes to sample size, statistical analysis based on interim analysis Safety event/information Amendment based on DSMB review comments Administrative change : e.g. study team member change Actual execution Well designed Exploratory nature We try to minimise but not possible to eliminate

8 Sponsor shall notify competent authorities (CA) and EC if protocol amendments are : Substantial amendment & Likely impact on trial subjects or Change the interpretation of the scientific documents or Otherwise significant How do they do it in EU? Sponsor and investigator shall take appropriate urgent safety measures to protect subjects against any immediate hazard and inform the CA and EC at the same time if New event relating to the conduct of the trial or the development of the investigational medicinal product and Likely to affect the safety of subjects Urgent safety measures may be taken without prior notification to the national competent authority. However, the sponsor must inform ex post the national competent authority and the Ethics Committee of the Member State concerned of the new events, the measures taken and the plan for further action as soon as possible.

9 What does ICH GCP say? 4.5 Compliance with Protocol Protocol should be conducted if obtained approval/favourable opinion by regulatory authority and IRB/IEC. Investigator should not implement any deviation from, or changes of the protocol prior review and documented approval/favourable opinion from IRB/IEC except : Where necessary to eliminate an immediate hazard(s) to trial subjects, or The change(s) involves only logistical or administrative aspects of the trial As soon as possible, the implemented deviation or change, the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be submitted: to the IRB/IEC for review and approval/favourable opinion, to the sponsor for agreement and, if required, to the regulatory authority(ies)

10 Safety Reporting in ICH Countries 5.16 Safety Informa1on: IB, interim analysis, DSMB update The sponsor is responsible for the ongoing safety evalua8on of the inves8ga8onal product(s) The sponsor should promptly no8fy all concerned Inves8gator(s)/ ins8tu8on (s) and the regulatory authority(ies) of findings that could affect adversely the safety of subjects, impact the conduct of the trial, or alter the IRB/IEC's approval/favourable opinion to con8nue the trial. Increasing SAE/SADR cases of specific trial that might be queried for justification. Safety alert letter globally for a SUSAR, triggered regulatory authority inspection to further determine if patient safety/welfare/ right is still protected and consideration of trial s continued execution Adverse Drug Reac1on Repor1ng : SUSAR update The sponsor should expedite the repor8ng to all concerned inves8gator (s)/ ins8tu8ons(s), to the IRB(s)/IEC(s), where required, and to the regulatory authority(ies) of all adverse drug reac8ons (ADRs) that are both serious and unexpected.

11 Example of IND notification to RA from Asian country Background: study early termination was related with safety concern Sponsor report to regulatory authority on 23 April 2010 with study termination notification letter and Dear Investigator letter 27 April 2010 : Queries from regulatory authority regarding Please submit a detailed reason statement. Please notify the decision of early termination to principal investigators and the IRE at each site promptly. Please check a clinical trial progress so far Please check all serious adverse events in country X Please set up a follow up plan for participating subjects' safety 17 May 2010 : Sponsor report to regulatory with completed response

12 Regulation evolving to smooth the study conduct In Country A, once a protocol has been approved by regulatory authority, if the subsequent protocol change (s) doesn t involve study design or safety aspect, the applicant should only obtain IRB/IEC s approval and with notification of reference to the regulatory authority. Align with ICH requirement in safety reporting Once a protocol has been approved by regulatory authority, PI/Sponsor need to submit SUSAR instead of individual SAE report to RA/EC. Simplified process

13 The role of Ethics Committee and Regulatory Authority Institutional Review Board (IRB) / Independent Ethics Committee (IEC) : ensure the protection of the rights, safety and well-being of human subjects involved in a trial by, among other things, reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects Clinical trial review and approval Clinical trial annual progress report and approval renewal EC inspection Continuing review the impact for subject safety and study integrity when there is protocol amendment, protocol deviation, SUSAR, IB update submitted to EC Regulatory Authority (RA) : Bodies having the power to regulate. In the ICH GCP guideline the expression Regulatory Authorities includes the authorities that review submitted clinical data and those that conduct inspections. Clinical trial related regulations management and harmonization with international related regulations Annual IRB/EC review and certification

14 Robust System/ Process Clear metric to deliver Timely feedback Continuous Improvement Commu nication Quality professional staffs/ High Performing Site/PI Training / Certification Site accreditation Excellent Team work Quality embedded into our daily practice to secure pt safety

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP. Role of IRB/IEC in GCP Benjamin Kuo, MD, Dr.PH, CIP. Institutional Review Board (IRB) An independent body constituted of medical, scientific and non scientific members Responsible for ensuring protection

More information

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's

More information

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.

More information

History and Principles of Good Clinical Practice

History and Principles of Good Clinical Practice History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices

More information

The Study Site Master File and Essential Documents

The Study Site Master File and Essential Documents The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010

More information

Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010

Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010 Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured

More information

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good

More information

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

More information

Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6)

Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Related Accreditation Elements: I.1.D., I.1.F., I-2, I.7.B., II.2.E., II.2.F., II.4.A.,

More information

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB

More information

Essential Documents for the Conduct of a Clinical Trial. Debra Dykhuis Associate Director RSO

Essential Documents for the Conduct of a Clinical Trial. Debra Dykhuis Associate Director RSO Essential Documents for the Conduct of a Clinical Trial Debra Dykhuis Associate Director RSO Introduction Rationale for choosing this topic AHC movement toward setting GCP (Good Clinical Practice) guidelines

More information

STANDARD OPERATING PROCEDURE FOR RESEARCH. Management of Essential Documents and Trial Folders

STANDARD OPERATING PROCEDURE FOR RESEARCH. Management of Essential Documents and Trial Folders STANDARD OPERATING PROCEDURE FOR RESEARCH Management of Essential Documents and Trial Folders Author Linda Ward Author s Job Title QA Coordinator Division Department Version number 2 Ref SOP/CLN/001/2

More information

Institutional Responsibilities in the Conduct of Schistosomiasis Research in the Community

Institutional Responsibilities in the Conduct of Schistosomiasis Research in the Community Institutional Responsibilities in the Conduct of Schistosomiasis Research in the Community Vicente Y. Belizario,, Jr. National Institutes of Health and College of Public Health University of the Philippines

More information

What is necessary to provide good clinical data for a clinical trial?

What is necessary to provide good clinical data for a clinical trial? What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction

More information

Good Clinical Practice 101: An Introduction

Good Clinical Practice 101: An Introduction Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological

More information

CNE Disclosures. To change this title, go to Notes Master

CNE Disclosures. To change this title, go to Notes Master CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion

More information

TRIAL MASTER FILE- SPONSORED

TRIAL MASTER FILE- SPONSORED gsop-06-04 - Management of TMF for ENHT/ WHHT Sponsored CTIMPs Page 1 of 16 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust TRIAL MASTER

More information

Vertex Investigator-Initiated Studies Program Overview

Vertex Investigator-Initiated Studies Program Overview Vertex Investigator-Initiated Studies Program Overview Our Goal To support independent, investigator-initiated research designed to advance scientific knowledge of disease states, patient populations,

More information

Regulator s Role in GCP

Regulator s Role in GCP Regulator s Role in GCP David A. Lepay, M.D., Ph.D. APEC GCP Inspection Workshop May 27, 2008 Objectives of this Talk Review the roles and responsibilities of the regulatory authority under GCP Identify

More information

Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL

Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,

More information

Quality Management in Clinical Trials

Quality Management in Clinical Trials CLINICAL CASE STUDY SERIES Quality Management in Clinical Trials Clinical trials are conducted to collect the data necessary to provide information for academia, industry, and regulators to make decisions

More information

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities

More information

This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an

This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an Music No audio Please review information shown to understand the general course navigation and available resources. Resources, such as the audio script, example forms, and website links, can be accessed

More information

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:

More information

To Certify or Not to Certify

To Certify or Not to Certify To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus November

More information

To Certify or Not to Certify Sandra Halvorson, BA, CCRP

To Certify or Not to Certify Sandra Halvorson, BA, CCRP To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II We have no financial relationships

More information

Management of Protocol Deviations, Violations and Urgent Safety Measures

Management of Protocol Deviations, Violations and Urgent Safety Measures This is a controlled document. The master document is posted on the JRO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

INTERIM SITE MONITORING PROCEDURE

INTERIM SITE MONITORING PROCEDURE INTERIM SITE MONITORING PROCEDURE 1. PURPOSE The purpose of this SOP is to describe the interim monitoring procedures conducted at Institution, according to GCP and other applicable local regulations.

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Acknowledgments... xi Introduction... xiii 1 The Clinical Research Coordinator (CRC)... 1 Background and Training of the CRC...1 Personality and Skills... 2 Where Do CRCs Work?... 2 CRC

More information

The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly

The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent

More information

CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN

CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN Document CEN TC 258/WG2 N15 (Draft # 6, June 2000) CEN TC 258 Committee Enquiry/ISO TC 194 Committee Draft EN ISO 14155 CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN SUBJECTS PART 2: CLINICAL INVESTIGATION

More information

Quality Monitoring Checklist

Quality Monitoring Checklist Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor

More information

OECD Recommendation on the Governance of Clinical Trials

OECD Recommendation on the Governance of Clinical Trials OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside

More information

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis The Monitoring Visit Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis Disclosure The information herein is not intended to

More information

GOOD CLINICAL PRACTICE*)

GOOD CLINICAL PRACTICE*) GOOD CLINICAL PRACTICE*) Guideline Title Good Clinical Practice*) Legislative basis Directive 75/318/EEC as amended Date of first adoption July 1990 This version July 1996 Date of entry into January 1997

More information

CLINICAL TRIAL IN MALAYSIA. Clinical Trial and Compliance Section National Pharmaceutical Control Bureau Ministry of Health Malaysia

CLINICAL TRIAL IN MALAYSIA. Clinical Trial and Compliance Section National Pharmaceutical Control Bureau Ministry of Health Malaysia CLINICAL TRIAL IN MALAYSIA Clinical Trial and Compliance Section National Pharmaceutical Control Bureau Ministry of Health Malaysia OUTLINE Introduction Regulation and Ethical Oversight of Clinical Trial

More information

ICH Topic E 6 (R1) Guideline for Good Clinical Practice. Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95)

ICH Topic E 6 (R1) Guideline for Good Clinical Practice. Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) European Medicines Agency July 2002 CPMP/ICH/135/95 ICH Topic E 6 (R1) Guideline for Good Clinical Practice Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) TRANSMISSION TO CPMP July

More information

Questions and Answers to the Annual Safety Report

Questions and Answers to the Annual Safety Report Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit

More information

2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials

2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials L1 2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager,

More information

Workshop on Quality Risk Management Making Trials Fit for Purpose

Workshop on Quality Risk Management Making Trials Fit for Purpose Clinical Trials Transformation Initiative Workshop on Quality Risk Management Making Trials Fit for Purpose Andy Lee SVP, Global Clinical Operations, Genzyme Corporation August 23/24, 2011 Hyatt Regency,

More information

Adventist HealthCare, Inc.

Adventist HealthCare, Inc. IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human

More information

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,

More information

Measures. SOP Number: UoA-NHSG-SOP-045 Version No: 1

Measures. SOP Number: UoA-NHSG-SOP-045 Version No: 1 Standard Operating Procedure: Management of Deviations, Breaches and Urgent Safety SOP Number: UoA-NHSG-SOP-045 Version No: 1 Author: Date: 27 th March 2015 (Patricia Burns, Research Governance Manager,

More information

Clinical Research Professional Certification & Preparing for the CCRP Exam

Clinical Research Professional Certification & Preparing for the CCRP Exam Clinical Research Professional Certification & Preparing for the CCRP Exam Signe Denmark, MS, CCRP Toni Mauney, CCRP SoCRA: Society of Clinical Research Associates SoCRA established the Certification Program

More information

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,

More information

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives

More information

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015

Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient

More information

Signature Requirements for the etmf

Signature Requirements for the etmf Wingspan Technology Signature Requirements for the etmf A Regulatory and Technological Assessment Kathie Clark Director, Product Management Wingspan Technology 1 November 2012 Signature Requirements for

More information

9.0 Protocol Violations, Deviations, and Exceptions. 9.1 Definitions

9.0 Protocol Violations, Deviations, and Exceptions. 9.1 Definitions 9.0 Protocol Violations, Deviations, and Exceptions 9.1 Definitions Protocol deviation(s): means a minor or administrative departure from the IRBapproved protocol procedures (e.g., the protocol, informed

More information

JDRF Scientific Guidelines for applicants Version/Date 002/Aug 2015 Version history 001/Jul 2011

JDRF Scientific Guidelines for applicants Version/Date 002/Aug 2015 Version history 001/Jul 2011 JDRF Scientific Guidelines for applicants Version/Date 002/Aug 2015 Version history 001/Jul 2011 Contents Introduction... 2 JDRF clinical terms of award... 3 Nonexempt human subject s research... 3 Full

More information

Study Monitoring Plan Template

Study Monitoring Plan Template Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &

More information

Serious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd

Serious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches Ian Gravenor Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches of GCP or the Trial Protocol Agenda Why report? The legislation MHRA Guidance document Timelines Actions

More information

ICH Topic E 6 Guideline for Good Clinical Practice NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) *

ICH Topic E 6 Guideline for Good Clinical Practice NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) * The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit ICH Topic E 6 Guideline for Good Clinical Practice Step 5, Consolidated Guideline 1.5.96 NOTE FOR GUIDANCE ON

More information

Job Profile Clinical Research Associate III (CRA)

Job Profile Clinical Research Associate III (CRA) PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,

More information

CHANGE OF MONITOR AT STUDY SITE No: CM.8 01 02 Effective Date: 15 April 2013 Version Date: 15 March 2013

CHANGE OF MONITOR AT STUDY SITE No: CM.8 01 02 Effective Date: 15 April 2013 Version Date: 15 March 2013 CONTENTS: 1. DEFINITIONS/REFERENCES 2. 2. PURPOSE 2. 3. SCOPE.2. 4. RESPONSABILITIES 2. 5. PROCEDURES...3. 5.1 Assessment of Need and Approval of Change of CRA... 3. 5.2 Project training......3. 5.3 Documentation

More information

NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1

NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental

More information

Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector

Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector Oversight of Clinical Trials in Europe - Member State perspective Gunnar Danielsson Senior Expert Pharmaceutical Inspector Oversight of Clinical Trials Oversight of clinical trials occur on many different

More information

UK Implementation of the EU Clinical Trial Directive 2001/20/EC:

UK Implementation of the EU Clinical Trial Directive 2001/20/EC: UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October

More information

ICRIN Seminar on EU Regulation of Clinical Trials

ICRIN Seminar on EU Regulation of Clinical Trials ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation

More information

The Ontario Cancer Research Ethics Board Overview

The Ontario Cancer Research Ethics Board Overview The Ontario Cancer Research Ethics Board Overview Research Ethics Research ethics review is vital to the advancement of ethically sound research. Before individuals can be enrolled in a research study,

More information

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010 Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health

More information

Investigator Responsibilities

Investigator Responsibilities Investigator Responsibilities Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 010 Version number: 1 Effective date: 01 June 2010 Review due: May 2011

More information

The New EU Clinical Trial Regulation Potential Impacts on Sites

The New EU Clinical Trial Regulation Potential Impacts on Sites The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty

More information

Differential Training by Job Function ACRP Job Analysis Results

Differential Training by Job Function ACRP Job Analysis Results Differential Training by Job Function ACRP Job Analysis Results Morgean Hirt, ACA, Director of Certification Association of Clinical Research Professionals Disclaimer The views and opinions expressed in

More information

Moving from Compliance to Competency for the Clinical Research Professional

Moving from Compliance to Competency for the Clinical Research Professional Click to Edit Master Title Style Moving from Compliance to Competency for the Clinical Research Professional Rebecca Li, PhD, Executive Director Building A Learning Community Among Key Stakeholders - 1

More information

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices

More information

Clinical evaluation Latest development in expectations EU and USA

Clinical evaluation Latest development in expectations EU and USA Clinical evaluation Latest development in expectations EU and USA Medical Devices: staying ahead of regulatory developments Gert Bos BSI Israel 22 April - Herzliya Copyright 2012 BSI. All rights reserved.

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

Job Profile Clinical Research Associate I/II (CRA)

Job Profile Clinical Research Associate I/II (CRA) PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed

More information

and Regulatory Aspects

and Regulatory Aspects Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics

More information

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise

More information

The Regulations and Regulatory Practices in the US and EU for Amendments During Drug Development

The Regulations and Regulatory Practices in the US and EU for Amendments During Drug Development The Regulations and Regulatory Practices in the US and EU for Amendments During Drug Development May 17, 2011 Beijing, China Alberto Grignolo, Ph.D Corporate Vice President, Global Strategy PAREXEL Consulting

More information

Staff Member Signature Date Direct Supervisor Related Mater Health Services Position Description attached. Theme Leader Signature Date.

Staff Member Signature Date Direct Supervisor Related Mater Health Services Position Description attached. Theme Leader Signature Date. POSITION DESCRIPTION Mothers and Babies Theme Position Title Division Position Purpose Position Scope Occupational Category and Level Reporting Relationship Review Date Next Review Due, Mothers and Babies

More information

Novartis Investigator Initiated Trials (IITs) Guidelines

Novartis Investigator Initiated Trials (IITs) Guidelines Novartis Investigator Initiated Trials (IITs) Guidelines Introduction and background As part of our commitment to delivering innovative therapies to patients worldwide, Novartis believes in the need to

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE FOR GOOD CLINICAL PRACTICE E6 Recommended

More information

RESEARCH INVOLVING HUMAN SUBJECTS

RESEARCH INVOLVING HUMAN SUBJECTS RESEARCH INVOLVING HUMAN SUBJECTS GUIDELINES FOR IRBS EXECUTIVE SUMMARY Principle 1. There is general agreement internationally that human biomedical research involving risk of harm to human subjects should

More information

JOINT RESEARCH AND DEVELOPMENT OFFICE. Standard Operating Procedure for Investigators and the Joint R&D Office Staff SOP 22

JOINT RESEARCH AND DEVELOPMENT OFFICE. Standard Operating Procedure for Investigators and the Joint R&D Office Staff SOP 22 JOINT RESEARCH AND DEVELOPMENT OFFICE Standard Operating Procedure for Investigators and the Joint R&D Office Staff SOP 22 Updated By Praseeda Thaikalloor Clinical trials Manager Joint R&D office for GOSH/ICH

More information

CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:

CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS: CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS: COMPARING AND CONTRASTING FDA MEDICAL DEVICE REGULATIONS FOR CLINICAL INVESTIGATORS WITH ISO 14155:2011 Introduction Today s clinical research landscape for

More information

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors

More information

Guideline for good clinical practice E6(R2)

Guideline for good clinical practice E6(R2) 1 2 3 23 July 2015 EMA/CHMP/ICH/135/1995 Committee for Human Medicinal Products 4 5 Step 2b Adopted by CHMP for release for consultation 23 July 2015 Start of public consultation 4 August 2015 End of consultation

More information

Principal Investigator and Sub Investigator Responsibilities

Principal Investigator and Sub Investigator Responsibilities Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal

More information

ICH Topic E 6 (R1) Guideline for Good Clinical Practice. Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95)

ICH Topic E 6 (R1) Guideline for Good Clinical Practice. Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) European Medicines Agency July 2002 CPMP/ICH/135/95 ICH Topic E 6 (R1) Guideline for Good Clinical Practice Step 5 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) TRANSMISSION TO CPMP July

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Estonia

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Estonia The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Estonia Question 1: What laws or regulations apply to an application for conducting a clinical

More information

Paediatric networks for clinical trial in children - regulatory authorities perspectives

Paediatric networks for clinical trial in children - regulatory authorities perspectives Paediatric networks for clinical trial in children - regulatory authorities perspectives Dr Chantal Bélorgey Head of clinical trial Dpt, Afssaps Chair of CTFG 11 March 2011 1 Context The clinical trials

More information

EU Clinical Trials Regulation Regulation EU 536/2014

EU Clinical Trials Regulation Regulation EU 536/2014 EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes

More information

Regulations & Requirements for Conducting Clinical Trials on Drugs

Regulations & Requirements for Conducting Clinical Trials on Drugs Regulations & Requirements for Conducting Clinical Trials on Drugs Version 1.0 Date issued Date of implementation 08/07/2015 08/07/2015 1 [SFDA Regulations & Requirements for Conducting Clinical Trials

More information

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality

More information

20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany

20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany 20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements

More information

Yale Cancer Center Data and Safety Monitoring Committee Charter

Yale Cancer Center Data and Safety Monitoring Committee Charter Yale Cancer Center Data and Safety Monitoring Committee Charter Purpose/Mission The purpose of the Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) is to provide ongoing data and safety

More information

ROLE OF THE RESEARCH COORDINATOR FDA INSPECTIONS-PREPARING for an Audit

ROLE OF THE RESEARCH COORDINATOR FDA INSPECTIONS-PREPARING for an Audit Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR FDA INSPECTIONS-PREPARING

More information

Biotech Concerto #3. European Clinical Trial Environment

Biotech Concerto #3. European Clinical Trial Environment Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart

More information

CLINICAL RESEARCH PROTOCOL CHECKLIST

CLINICAL RESEARCH PROTOCOL CHECKLIST CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND

More information

Protocol Deviations, Non-Compliance and Serious Breaches

Protocol Deviations, Non-Compliance and Serious Breaches Protocol Deviations, Non-Compliance Clinical Trials SOP Reference ID: Noclor/Spon/S10/01 Version Number 1.0 Effective Date: 1 st March 2016 It is the responsibility of all users of this SOP to ensure that

More information

Site Initiation and Close Out (Sponsored Clinical Trials)

Site Initiation and Close Out (Sponsored Clinical Trials) Site Initiation and Close Out (Sponsored Clinical Trials) Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 008 Version number: 1 Effective date: 01 June

More information

Annex A. Levels 1 5 of the Clinical Research Coordinator Track in the Clinical Research WSQ Framework

Annex A. Levels 1 5 of the Clinical Research Coordinator Track in the Clinical Research WSQ Framework Annex A Levels 1 5 of the Clinical Research Coordinator Track in the Clinical Research WSQ Framework WSQ Higher Certificate in Clinical Research (Clinical Research Coordinators) Apply Drug Development

More information

Post-authorisation safety studies

Post-authorisation safety studies Post-authorisation safety studies 7th SME Workshop "Focus on Pharmacovigilance" 19 April 2012 Presented by: Xavier Kurz An agency of the European Union Directive 2010/84/EU Article 21a added ( ) a marketing

More information

CLINICAL RESEARCH IN EUROPE AFTER THE EU DIRECTIVE ON CLINICAL TRIALS. DOMENICO CRISCUOLO, MD, FFPM CMO at CREABILIS THERAPEUTICS IFAPP PAST PRESIDENT

CLINICAL RESEARCH IN EUROPE AFTER THE EU DIRECTIVE ON CLINICAL TRIALS. DOMENICO CRISCUOLO, MD, FFPM CMO at CREABILIS THERAPEUTICS IFAPP PAST PRESIDENT CLINICAL RESEARCH IN EUROPE AFTER THE EU DIRECTIVE ON CLINICAL TRIALS DOMENICO CRISCUOLO, MD, FFPM CMO at CREABILIS THERAPEUTICS IFAPP PAST PRESIDENT EU : SOME FACTS 25 MEMBERS + 3 CANDIDATES 500.000.000

More information

through advances in risk-based

through advances in risk-based Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform

More information

This policy applies to all clinical research conducted at Beaumont Health System.

This policy applies to all clinical research conducted at Beaumont Health System. CLINICAL RESEARCH QUALITY AND PROCESS IMPROVEMENT PROGRAM 113 1 of 6 PURPOSE Prior The purpose of this policy is to provide an overview of the Clinical Research Quality and Process Improvement Program

More information